{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T08:46:42Z","timestamp":1777970802374,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007176","name":"Scuola Superiore Sant'Anna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007176","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The significant morbidity and mortality associated with heart failure with reduced (HFrEF) or preserved ejection fraction (HFpEF) justify the search for novel therapeutic agents. The nitric oxide (NO)\u2013soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway plays an important role in the regulation of cardiovascular function. This pathway is disrupted in HF resulting in decreased protection against myocardial injury. The sGC activator cinaciguat increases cGMP levels by direct, NO-independent activation of sGC, and may be particularly effective in conditions of increased oxidative stress and endothelial dysfunction, and then reduced NO levels, but this comes at the expense of a greater risk of hypotension. Conversely, sGC stimulators (riociguat and vericiguat) enhance sGC sensitivity to endogenous NO, and then exert a more physiological action. The phase 3 VICTORIA trial found that vericiguat is safe and effective in patients with HFrEF and recent HF decompensation. Therefore, adding vericiguat may be considered in individual patients with HFrEF, particularly those at higher risk of HF hospitalization; the efficacy of the sacubitril\/valsartan-vericiguat combination in HFrEF is currently unknown.<\/jats:p>","DOI":"10.1007\/s10741-021-10146-1","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T18:03:52Z","timestamp":1626890632000},"page":"1165-1171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-9519","authenticated-orcid":false,"given":"Alberto","family":"Aimo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Panichella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Mario","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"10146_CR1","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ et al (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891\u2013975","DOI":"10.1002\/ejhf.592"},{"issue":"6","key":"10146_CR2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM et al (2017) 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70(6):776\u2013803","journal-title":"J Am Coll Cardiol"},{"issue":"9744","key":"10146_CR3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M, Borer JS, Ford I, Dubost-Brama A et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (London, England) 376(9744):875\u2013885","journal-title":"Lancet (London, England)"},{"issue":"11","key":"10146_CR4","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993\u20131004","journal-title":"N Engl J Med"},{"issue":"15","key":"10146_CR5","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424","journal-title":"N Engl J Med"},{"issue":"21","key":"10146_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008","journal-title":"N Engl J Med"},{"issue":"10254","key":"10146_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G et al (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet (London, England) 396(10254):819\u2013829","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10146_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2025797","volume":"384","author":"JR Teerlink","year":"2021","unstructured":"Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD et al (2021) cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med 384(2):105\u2013116","journal-title":"N Engl J Med"},{"key":"10146_CR9","doi-asserted-by":"crossref","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J et al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Eng J Med","DOI":"10.1056\/NEJMoa1915928"},{"issue":"6","key":"10146_CR10","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S (2020) Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Translation Sci 5(6):632\u2013644","journal-title":"JACC Basic Translation Sci"},{"issue":"4","key":"10146_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jchf.2019.12.001","volume":"8","author":"JR Teerlink","year":"2020","unstructured":"Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD et al (2020) Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF. JACC Heart Fail 8(4):329\u2013340","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10146_CR12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jchf.2013.03.003","volume":"1","author":"D Gupta","year":"2013","unstructured":"Gupta D, Georgiopoulou VV, Kalogeropoulos AP, Marti CN, Yancy CW, Gheorghiade M et al (2013) Nitrate therapy for heart failure: benefits and strategies to overcome tolerance. JACC Heart Fail 1(3):183\u2013191","journal-title":"JACC Heart Fail"},{"key":"10146_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/164_2016_100","volume":"243","author":"S Breitenstein","year":"2017","unstructured":"Breitenstein S, Roessig L, Sandner P, Lewis KS (2017) Novel sGC stimulators and sGC activators for the treatment of heart failure. Handb Exp Pharmacol 243:225\u2013247","journal-title":"Handb Exp Pharmacol"},{"key":"10146_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/164_2016_82","volume":"243","author":"GE Kim","year":"2017","unstructured":"Kim GE, Kass DA (2017) Cardiac phosphodiesterases and their modulation for treating heart disease. Handb Exp Pharmacol 243:249\u2013269","journal-title":"Handb Exp Pharmacol"},{"issue":"15","key":"10146_CR15","first-page":"1244","volume":"104","author":"DC Hutchings","year":"2018","unstructured":"Hutchings DC, Anderson SG, Caldwell JL, Trafford AW (2018) Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? Heart (British Cardiac Soc) 104(15):1244\u20131250","journal-title":"Heart (British Cardiac Soc)"},{"issue":"15","key":"10146_CR16","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.jacc.2020.08.031","volume":"76","author":"M Emdin","year":"2020","unstructured":"Emdin M, Aimo A, Castiglione V, Vergaro G, Georgiopoulos G, Saccaro LF et al (2020) Targeting cyclic guanosine monophosphate to treat heart failure: JACC review topic of the week. J Am Coll Cardiol 76(15):1795\u20131807","journal-title":"J Am Coll Cardiol"},{"key":"10146_CR17","doi-asserted-by":"crossref","unstructured":"Volpe M, Carnovali M, Mastromarino V (2016) The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clinical science (London, England 1979). 130(2):57\u201377","DOI":"10.1042\/CS20150469"},{"issue":"1","key":"10146_CR18","doi-asserted-by":"publisher","first-page":"H17","DOI":"10.1152\/ajpheart.00684.2005","volume":"290","author":"A Clerico","year":"2006","unstructured":"Clerico A, Recchia FA, Passino C, Emdin M (2006) Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 290(1):H17-29","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10146_CR19","doi-asserted-by":"crossref","unstructured":"Aimo A, Castiglione V, Borrelli C, Saccaro LF, Franzini M, Masi S et al (2019) Oxidative stress and inflammation in the evolution of heart failure: from pathophysiology to therapeutic strategies. Euro J Prevent Cardio 2047487319870344","DOI":"10.1177\/2047487319870344"},{"issue":"9","key":"10146_CR20","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/eurjhf\/hfs093","volume":"14","author":"M Gheorghiade","year":"2012","unstructured":"Gheorghiade M, Greene SJ, Filippatos G, Erdmann E, Ferrari R, Levy PD et al (2012) Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail 14(9):1056\u20131066","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10146_CR21","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","volume":"128","author":"D Bonderman","year":"2013","unstructured":"Bonderman D, Ghio S, Felix SB, Ghofrani HA, Michelakis E, Mitrovic V et al (2013) Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128(5):502\u2013511","journal-title":"Circulation"},{"issue":"7","key":"10146_CR22","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1023\/A:1016473601633","volume":"19","author":"LX Yu","year":"2002","unstructured":"Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP et al (2002) Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res 19(7):921\u2013925","journal-title":"Pharm Res"},{"key":"10146_CR23","doi-asserted-by":"crossref","unstructured":"Boettcher M, Thomas D, Mueck W, Loewen S, Arens E, Yoshikawa K et al (2020) Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. Euro J Clin Pharmacol","DOI":"10.1007\/s00228-020-03023-7"},{"issue":"12","key":"10146_CR24","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","volume":"60","author":"M Follmann","year":"2017","unstructured":"Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A et al (2017) Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure. J Med Chem 60(12):5146\u20135161","journal-title":"J Med Chem"},{"issue":"11","key":"10146_CR25","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s40262-020-00895-x","volume":"59","author":"M Boettcher","year":"2020","unstructured":"Boettcher M, Gerisch M, Lobmeyer M, Besche N, Thomas D, Gerrits M et al (2020) Metabolism and pharmacokinetic drug-drug interaction profile of vericiguat, a soluble guanylate cyclase stimulator: results from preclinical and phase I healthy volunteer studies. Clin Pharmacokinet 59(11):1407\u20131418","journal-title":"Clin Pharmacokinet"},{"issue":"21","key":"10146_CR26","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","volume":"314","author":"M Gheorghiade","year":"2015","unstructured":"Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP et al (2015) Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED Randomized Trial. JAMA 314(21):2251\u20132262","journal-title":"JAMA"},{"issue":"9","key":"10146_CR27","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/ejhf.1787","volume":"22","author":"F Kramer","year":"2020","unstructured":"Kramer F, Voss S, Roessig L, Igl BW, Butler J, Lam CSP et al (2020) Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. Eur J Heart Fail 22(9):1675\u20131683","journal-title":"Eur J Heart Fail"},{"key":"10146_CR28","doi-asserted-by":"crossref","unstructured":"Pieske B, Patel MJ, Westerhout CM, Anstrom KJ, Butler J, Ezekowitz J et al (2019) Baseline features of the VICTORIA (vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. Eur J Heart Fail","DOI":"10.1002\/ejhf.1664"},{"issue":"2","key":"10146_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jchf.2017.08.013","volume":"6","author":"PW Armstrong","year":"2018","unstructured":"Armstrong PW, Roessig L, Patel MJ, Anstrom KJ, Butler J, Voors AA et al (2018) A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial. JACC Heart Fail 6(2):96\u2013104","journal-title":"JACC Heart Fail"},{"issue":"11","key":"10146_CR30","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","volume":"8","author":"JA Ezekowitz","year":"2020","unstructured":"Ezekowitz JA, O\u2019Connor CM, Troughton RW, Alemayehu WG, Westerhout CM, Voors AA et al (2020) N-terminal pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study. JACC Heart Fail 8(11):931\u2013939","journal-title":"JACC Heart Fail"},{"key":"10146_CR31","unstructured":"Lam CSP, Giczewska A, Sliwa K, Edelmann F, Refsgaard J, Bocchi E et al (2020) Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA Trial. JAMA Cardio"},{"issue":"16","key":"10146_CR32","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/sim.1201","volume":"21","author":"T Lumley","year":"2002","unstructured":"Lumley T (2002) Network meta-analysis for indirect treatment comparisons. Stat Med 21(16):2313\u20132324","journal-title":"Stat Med"},{"issue":"7521","key":"10146_CR33","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","volume":"331","author":"DM Caldwell","year":"2005","unstructured":"Caldwell DM, Ades AE, Higgins JP (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ (Clinical research ed) 331(7521):897\u2013900","journal-title":"BMJ (Clinical research ed)"},{"key":"10146_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1741-7015-9-79","volume":"9","author":"T Li","year":"2011","unstructured":"Li T, Puhan MA, Vedula SS, Singh S, Dickersin K (2011) Network meta-analysis-highly attractive but more methodological research is needed. BMC Med 9:79","journal-title":"BMC Med"},{"key":"10146_CR35","doi-asserted-by":"crossref","unstructured":"Aimo A, Pateras K, Stamatelopoulos K, Bayes-Genis A, Lombardi CM, Passino C et al (2020) Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis. Cardiovasc Drugs Ther","DOI":"10.1007\/s10557-020-07099-2"},{"issue":"5","key":"10146_CR36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.carpath.2011.11.007","volume":"21","author":"CD Kemp","year":"2012","unstructured":"Kemp CD, Conte JV (2012) The pathophysiology of heart failure. Cardiovasc Pathol 21(5):365\u2013371","journal-title":"Cardiovasc Pathol"},{"issue":"20","key":"10146_CR37","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J et al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382(20):1883\u20131893","journal-title":"N Engl J Med"},{"issue":"9","key":"10146_CR38","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","volume":"15","author":"JJ McMurray","year":"2013","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al (2013) Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 15(9):1062\u20131073","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10146_CR39","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","volume":"5","author":"SD Solomon","year":"2017","unstructured":"Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J et al (2017) Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF Trial. JACC Heart Fail 5(7):471\u2013482","journal-title":"JACC Heart Fail"},{"key":"10146_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ahj.2018.01.004","volume":"198","author":"EJ Velazquez","year":"2018","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, Ambrosy AP, Duffy CI, McCague K et al (2018) Rationale and design of the comParIson Of sacubitril\/valsartaN versus enalapril on effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. Am Heart J 198:145\u2013151","journal-title":"Am Heart J"},{"key":"10146_CR41","doi-asserted-by":"crossref","unstructured":"Khan MS, Felker GM, Pi\u00f1a IL, Camacho A, Bapat D, Ibrahim NE et al (2020) Reverse cardiac remodeling following initiation of sacubitril\/valsartan in patients with heart failure with and without diabetes. JACC Heart Fail","DOI":"10.1016\/j.jchf.2020.09.014"},{"issue":"16","key":"10146_CR42","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1161\/CIRCULATIONAHA.106.643536","volume":"115","author":"E Takimoto","year":"2007","unstructured":"Takimoto E, Belardi D, Tocchetti CG, Vahebi S, Cormaci G, Ketner EA et al (2007) Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation 115(16):2159\u20132167","journal-title":"Circulation"},{"issue":"4","key":"10146_CR43","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E (2020) Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol 75(4):422\u2013434","journal-title":"J Am Coll Cardiol"},{"key":"10146_CR44","doi-asserted-by":"crossref","unstructured":"Straw S, McGinlay M, Witte KK (2021) Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. Open Heart 8(1)","DOI":"10.1136\/openhrt-2021-001585"},{"issue":"4","key":"10146_CR45","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cjca.2021.01.017","volume":"37","author":"M McDonald","year":"2021","unstructured":"McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N et al (2021) CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol 37(4):531\u2013546","journal-title":"Can J Cardiol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-021-10146-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-021-10146-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-021-10146-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T09:37:33Z","timestamp":1699263453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-021-10146-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10146"],"URL":"https:\/\/doi.org\/10.1007\/s10741-021-10146-1","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"8 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.E. has received consulting fees from Merck; M.M. has received consulting fees from Bayer, Fresenius, Novartis, and Windtree Therapeutics for participation to advisory boards or executive committees of clinical trials; M.S. has received consulting fees from Bayer, Merck, Novartis, Vifor Farma, Abbott, Boehringer Ingelhein, AstraZeneca, Bioventrix, Servier; M.E. and M.S. are the Italian national leader investigators of VICTORIA. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}